[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vaccination or natural immunity", "description": "COVID-19 vaccine mandates should not discriminate against natural immunity, The unnaturalistic fallacy\n\nhttps://jme.bmj.com/content/48/6/371\n\nCOVID-19 vaccine requirements, debate,\n\npolicies should have recognised proof of natural immunity,\n\nsufficient basis for exemption to vaccination requirements. \n\nArguments\n\nTwo implausible claims about natural immunity: \n\nNatural immunity is superior to \u2018artificial\u2019 immunity\n\nIt is better to acquire immunity through natural infection\n\nNaturalistic fallacy (many things are natural, but not good)\n\n(A natural public health strategy, increased overall morbidity and mortality)\n\nWe lack clear and convincing scientific evidence that vaccine-induced immunity has a significantly higher protective effect than natural immunity.\n\nVaccine requirements represent a substantial infringement of individual liberty, and other significant costs\n\nCan only be justified if they are necessary for achieving a proportionate public health benefit. \n\nWithout compelling evidence for the superiority of vaccine-induced immunity, it cannot be deemed necessary to require vaccination for those with natural immunity. \n\n\u2018vaccine passports\u2019 \u2018health passes\u2019 \n\nRationale for vaccine mandates\n\nPreventing healthcare systems becoming overwhelmed, (staff and patients)\n\nReducing community viral transmission\n\nAcquired immunity naturally, potentially equivalent to vaccination immunity\n\nThis is the unnaturalistic fallacy as opposed to the naturalistic fallacy\n\nNatural immunity and vaccine-induced immunity, evidence\n\nEquivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis\n\nhttps://www.cureus.com/articles/72074-e\n\nAll of the included studies found at least statistical equivalence between the protection of full vaccination and natural immunity; \n\nand, three studies found superiority of natural immunity. \n\nNNT to prevent one annual case of infection in COVID-recovered patients 218\n\nNNT COVID-na\u00efve patients, 6.5\n\n33.5-fold difference in benefit between the two populations\n\nour review demonstrates that natural immunity in COVID-recovered individuals is, at least, equivalent to the protection afforded by complete vaccination of COVID-na\u00efve populations \n\nVaccinations for recovered people, marginal on an absolute basis. \n\nOmicron in adults aged 65 or over\n\nminimal or no effect against mild disease with the Omicron variant from 20 weeks after the second dose of ChAdOx1-S or BNT162b2\n\ndata are beginning to emerge which suggest that the effect of the vaccines on transmission may diminish within a matter of months\n\nImmunological memory to SARS-CoV-2 assessed for up to 8 months after infection\n\nhttps://www.science.org/doi/abs/10.1126/science.abf4063\nImmunological memory is the basis for durable protective immunity after infections or vaccinations. \n\nSubstantial immune memory is generated after COVID-19, involving,\n\nmemory B cells, antibodies, memory CD4+Tcells, memoryCD8+T cells.\n\nCirculating antibody titers were not predictive of T cell memory.\n\nDo not reflect the richness and durability of immune memory to SARS-CoV-2.\n\nReinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study\n\nhttps://academic.oup.com/cid/article/73/10/1882/6170939?login=true\n\nN = 150,325 patients\n\n8,845 (5.9%)\n\n141,480 (94.1%)\n\nProtection against reinfection, 81.8%\n\nProtection against symptomatic reinfection, 84.5%\n\nRisk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden\n\nhttps://www.sciencedirect.com/science/article/pii/S1473309922001438\n\nCohort one, 2,039,106 \n\nCohort two, 962,318 one dose\n\nCohort three, 567,810 two doses\n\n767 individuals with natural immunity needed to be vaccinated to prevent one reinfection\n\nProtection against the Omicron Variant from Previous SARS-CoV-2 Infection\n\nhttps://www.nejm.org/doi/full/10.1056/nejmc2200133\n\nProtection from prior infection against severe outcomes from Omicron remained robust, 87.8%\n\nReinfection often occurs with negligible symptoms and high Ct values, indicating reduced epidemiologic significance\n\nThe case for natural immunity exemptions\n\nVaccine requirements have significant costs\n\nSubstantial infringement of individual liberty\n\nThere are non-trivial risks associated with vaccination\n\nThe Biopharmaceutical Industry Provides 75% Of The FDA's Drug Review Budget. Is This A Problem?\nhttps://www.forbes.com/sites/johnlamattina/2018/06/28/the-biopharmaceutical-industry-provides-75-of-the-fdas-drug-review-budget-is-this-a-problem/?sh=5dc27d7649ec", "link": "https://www.youtube.com/watch?v=eGUJJIdjVSQ", "date_published": "2022-06-21 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]